Emcure Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	2,580	2,101	+22.8%
EBITDA	532	417	+27.8%
EBITDA margin	20.6%	19.8%	+0.8 pts
Profit before tax	394	291	+35.3%
Net profit	292	215	+36.2%
EPS	₹15.50	₹10.92	+41.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024

Expenses
	2,580	2,470	2,363	2,270	2,101	2,116	1,963	2,002	1,815
	2.1	4.0	1.9	3.1	3.7	4.5	3.9	35.7	23.4
	2,583	2,474	2,365	2,273	2,104	2,121	1,967	2,038	1,839
	481	419	421	420	433	404	400	391	332
	555	661	560	625	550	572	429	502	380
	36.9	−77.0	−18.9	−156	−181	−83.6	−46.0	−105	−28.8
	409	387	387	385	393	373	367	356	350
	31.5	46.4	38.0	32.5	26.8	39.0	31.8	46.2	58.8
	110	106	105	105	99.5	96.8	96.8	96.9	93.6
	565	600	521	520	488	448	458	477	445
	2,189	2,143	2,013	1,932	1,810	1,850	1,737	1,764	1,631
	532	480	493	475	417	402	355	381	336
	423	373	388	371	317	306	258	284	243
Profit
	394	331	352	341	294	271	230	273	207
	0.0	10.3	−38.2	0.0	−3.5	−10.4	0.0	0.0	0.0
	394	341	314	341	291	261	230	273	207
	115	111	102	93.0	86.0	91.6	58.9	79.8	61.9
	−14.2	−13.7	−19.9	−3.0	−10.1	−28.2	14.9	−7.9	−7.1
	101	97.4	82.4	90.0	76.0	63.4	73.8	71.9	54.8
	292	244	231	251	215	197	156	202	153
	292	244	231	251	215	197	156	202	153
	20.7	33.0	25.4	28.1	79.6	28.4	−58.3	63.0	−1.6
	313	277	257	279	294	226	97.8	265	151
	294	243	231	243	207	189	154	195	144
	−1.5	0.3	0.8	7.9	7.8	8.3	2.4	7.0	8.5
Per share
	₹15.50	₹12.84	₹12.16	₹12.85	₹10.92	₹9.97	₹8.12	₹10.33	₹7.95
	₹15.50	₹12.84	₹12.16	₹12.85	₹10.92	₹9.97	₹8.12	₹10.33	₹7.95
Other comprehensive income — detail
	20.7	33.0	25.4	28.1	79.6	28.4	—	—	—
	−0.2	2.7	−0.3	−0.5	−0.8	−2.9	−0.2	−0.2	−0.3
	−0.0	0.8	−0.1	−0.1	−0.2	−0.8	—	—	—
	—	—	—	—	—	—	−0.1	−0.0	−0.1
	20.9	31.1	25.6	28.4	80.1	30.6	−58.2	63.1	−1.4
	315	276	256	272	287	218	95.4	258	142
	−1.5	0.4	0.8	7.9	7.8	8.0	2.4	7.0	8.5
Per share — as-filed variants
	₹15.50	₹12.84	₹12.16	₹12.85	₹10.92	₹9.97	₹8.12	₹10.33	₹7.95
	₹15.50	₹12.84	₹12.16	₹12.85	₹10.92	₹9.97	₹8.12	₹10.33	₹7.95
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,507	1,467	1,401	1,380	1,299	1,224	1,180	1,213	1,132
	58.4%	59.4%	59.3%	60.8%	61.8%	57.8%	60.1%	60.6%	62.4%
Adjusted (ex-exceptional items) — derived
	394	331	352	341	294	271	230	273	207
	0.0	10.3	−38.2	0.0	−3.5	−10.4	0.0	0.0	0.0
	292	236	259	251	217	205	156	202	153
	₹15.50	₹12.45	₹13.64	₹12.85	₹11.05	₹10.37	₹8.12	₹10.33	₹7.95

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

EMCURE₹1,775.90

Emcure Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMANKIND ALKEM TORNTPHARM ERIS GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹33,669 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,815.1	2,002.0	1,962.6	2,116.2	2,100.5	2,269.8	2,363.5	2,469.7	2,580.4
Other Income	23.4	35.7	3.9	4.5	3.7	3.1	1.9	4.0	2.1
Total Income	1,838.6	2,037.6	1,966.5	2,120.7	2,104.2	2,272.9	2,365.3	2,473.7	2,582.5
Expenses
+ Cost of Materials Consumed	331.7	391.5	399.8	403.9	432.5	420.5	421.2	418.6	481.1
+ Purchases of Stock-in-Trade	380.1	502.3	428.9	571.9	550.5	625.2	560.1	661.5	555.1
+ Changes in Inventories	-28.8	-105.1	-46.0	-83.6	-181.0	-156.1	-18.9	-77.0	36.9
+ Employee Benefit Expense	350.4	355.6	366.9	373.4	393.5	384.6	387.3	386.8	409.5
+ Finance Costs	58.8	46.2	31.8	39.0	26.8	32.5	38.0	46.4	31.5
+ Depreciation & Amortisation	93.6	96.9	96.8	96.8	99.5	104.6	104.7	106.3	109.5
+ Other Expenses	445.3	476.9	458.4	448.4	488.3	520.2	521.0	600.3	565.3
Total Expenses	1,631.2	1,764.2	1,736.6	1,849.7	1,810.0	1,931.5	2,013.4	2,142.8	2,189.0
EBITDA	336.3	380.9	354.6	402.4	416.8	475.5	492.7	479.6	532.5
EBIT	242.7	284.0	257.8	305.6	317.3	370.8	388.1	373.3	423.0
Profit
PBT before Exceptional Items	207.4	273.4	229.9	271.0	294.3	341.4	351.9	330.9	393.5
+ Exceptional Items	0.0	0.0	0.0	-10.4	-3.5	0.0	-38.2	10.3	0.0
Pretax Income	207.4	273.4	229.9	260.6	290.8	341.4	313.8	341.2	393.5
+ Current Tax	61.9	79.8	58.9	91.6	86.0	93.0	102.4	111.2	115.2
+ Deferred Tax	-7.1	-7.9	14.9	-28.2	-10.1	-3.0	-19.9	-13.7	-14.2
Tax Expense	54.8	71.9	73.8	63.4	76.0	90.0	82.4	97.4	101.0
Net Income	152.6	201.5	156.1	197.2	214.8	251.4	231.4	243.7	292.5
+ Net Income — Continuing Ops	152.6	201.5	156.1	197.2	214.8	251.4	231.4	243.7	292.5
+ Other Comprehensive Income	-1.6	63.0	-58.3	28.4	79.6	28.1	25.4	33.0	20.7
Total Comprehensive Income	151.0	264.5	97.8	225.7	294.4	279.5	256.8	276.8	313.2
Net Income to Common	144.1	194.6	153.7	189.0	207.0	243.5	230.5	243.4	294.0
Minority Interest	8.5	7.0	2.4	8.3	7.8	7.9	0.8	0.3	-1.5
Per Share
Basic EPS	7.95	10.33	8.12	9.97	10.92	12.85	12.16	12.84	15.50
Diluted EPS	7.95	10.33	8.12	9.97	10.92	12.85	12.16	12.84	15.50
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	28.4	79.6	28.1	25.4	33.0	20.7
+ Items NOT to be Reclassified to P&L	-0.3	-0.2	-0.2	-2.9	-0.8	-0.5	-0.3	2.7	-0.2
+ Tax on Items NOT to be Reclassified	—	—	—	-0.8	-0.2	-0.1	-0.1	0.8	-0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.0	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-1.4	63.1	-58.2	30.6	80.1	28.4	25.6	31.1	20.9
Comprehensive Income — Owners of Parent	142.5	257.5	95.4	217.6	286.6	271.6	256.0	276.4	314.7
Comprehensive Income — Non-controlling Interests	8.5	7.0	2.4	8.0	7.8	7.9	0.8	0.4	-1.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	7.95	10.33	8.12	9.97	10.92	12.85	12.16	12.84	15.50
Diluted EPS — Continuing Operations	7.95	10.33	8.12	9.97	10.92	12.85	12.16	12.84	15.50
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,132.0	1,213.3	1,179.9	1,224.1	1,298.5	1,380.3	1,401.0	1,466.6	1,507.3
Gross Margin %	62.37	60.61	60.12	57.84	61.82	60.81	59.28	59.38	58.41
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	207.4	273.4	229.9	271.0	294.3	341.4	351.9	330.9	393.5
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-10.4	-3.5	0.0	-38.2	10.3	0.0
Net Income Adj (tax-effected)	152.6	201.5	156.1	205.1	217.4	251.4	259.5	236.4	292.5
EPS Adj	7.95	10.33	8.12	10.37	11.05	12.85	13.64	12.45	15.50
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	181.2	189.1	189.4	189.5	189.5	189.6	189.6	189.6	189.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Emcure Pharmaceuticals Q2 FY27 results date

Emcure Pharmaceuticals (NSE: EMCURE) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 14 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹294 crore, up 42.1% from ₹207 crore in Q1 FY26 and up 20.8% from ₹243 crore in Q4 FY26. Revenue from operations was ₹2,580 crore, up 22.8% year on year and up 4.5% from the previous quarter.

Board-meeting notice filed: 14 October 2026
Q2 FY26 results (a year earlier): 11 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 14 Oct
Q1 FY27 net profit: ₹294 Cr+42.1% vs Q1 FY26+20.8% vs Q4 FY26
Q1 FY27 revenue: ₹2,580 Cr+22.8% vs Q1 FY26+4.5% vs Q4 FY26
Q1 FY27 operating margin: 16.4%+1.3 pts vs Q1 FY26+1.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹243 CrRevenue ₹2,270 Cr
Q1 FY27 EPS (basic): ₹15.50

Questions

When will Emcure Pharmaceuticals announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 14 October 2026). Last year it reported Q2 FY26 on 11 November 2025.

What will Emcure Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹243 crore and revenue from operations ₹2,270 crore. The latest quarter, Q1 FY27, had a net profit of ₹294 crore and revenue of ₹2,580 crore.

What were Emcure Pharmaceuticals' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹294 crore, up 42.1% from ₹207 crore in Q1 FY26 and up 20.8% from ₹243 crore in Q4 FY26. Revenue from operations was ₹2,580 crore, up 22.8% year on year and up 4.5% from the previous quarter.

How has Emcure Pharmaceuticals' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹243 crore in Q2 FY26, ₹231 crore in Q3 FY26, ₹243 crore in Q4 FY26 and ₹294 crore in Q1 FY27. That is ₹1,011 crore over the four quarters, up 35.9% from ₹744 crore in the four quarters before. Revenue from operations: ₹2,270 crore, ₹2,363 crore, ₹2,470 crore and ₹2,580 crore.

What was Emcure Pharmaceuticals' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹924 crore in FY26 (April 2025–March 2026), up 35.7% from ₹681 crore in FY25.

What was Emcure Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹9,204 crore in FY26 (April 2025–March 2026), up 16.6% from ₹7,896 crore in FY25.

Where do these Emcure Pharmaceuticals figures come from?

From Emcure Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.